Cargando…
SUN-042 Low Dose Cyproterone Acetate for the Treatment of Transgender Women - a Retrospective Study
Introduction: Transgender women with intact gonads receive lifelong hormonal treatment in order to suppress physiologic androgen production. Cyproterone acetate (CA) is the most comon antiandrogenic drug prescribed for this indication in Europe, with a dose range between 25-100 mg/day. Aim: To asses...
Autores principales: | Even-Zohar, Naomi, Sofer, Yael, Yaish, Iris, Serebro, Merav, Tordjman, Karen, Greenman, Yona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7208009/ http://dx.doi.org/10.1210/jendso/bvaa046.1412 |
Ejemplares similares
-
A Cross Sectional Analysis of the Prevalence of Co-Morbidities in Older Transgender Individuals Receiving Hormone Affirming Therapy in Comparison With the General Population
por: Breda, Ido, et al.
Publicado: (2021) -
OR25-5 High Prevalence of Psychopathologies Among Transgender Subjects Presenting at a Large Tertiary Transgender Health Center: Implication for the Treating Clinicians
por: Kerem, Gil, et al.
Publicado: (2019) -
OR11-3 Evidence for Preserved Ovarian Reserve in Transgender Men Receiving Testosterone Therapy: Anti-Mullerian Hormone Serum Levels Decrease Modestly after One Year of Treatment
por: Yaish, Iris, et al.
Publicado: (2019) -
SAT409 Sublingual Estradiol Only, Compared To Combined Oral Estradiol And Cyproterone Acetate,Offers No Apparent Advantage For Gender Affirming Hormone Therapy (GHAT), In Treatment Naïve Transwomen: Results Of A Prospective Pilot Study
por: Yaish, Iris, et al.
Publicado: (2023) -
Endocrinology specialty service for inpatients: an unmet growing need
por: Osher, Esther, et al.
Publicado: (2023)